Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest IMS Health Stories

2013-02-11 12:24:56

PORTLAND, Maine, Feb. 11, 2013 /PRNewswire/ -- Putney, Inc., a rapidly growing pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has launched generic veterinary Cefpodoxime Proxetil tablets. Putney's veterinary Cefpodoxime Proxetil is the first and only generic approved by the FDA's Center for Veterinary Medicine (CVM) as equivalent to Simplicef®. Putney's generic Cefpodoxime Proxetil is FDA CVM approved to treat certain skin infections...

2013-01-23 12:27:34

BOSTON, Jan. 23, 2013 /PRNewswire/ -- TPG has signed a definitive agreement to acquire Eze Castle Software, a premier provider of global order management and related investment technologies, and RealTick, a leading multi?broker, cross?asset electronic execution platform, from ConvergEx Group. This all cash transaction is expected to close in Q1 or Q2 of 2013. Financial terms were not disclosed. The newly formed company will be called Eze Software Group. Following the close of the transaction,...

2013-01-22 12:28:03

MUMBAI and BALTIMORE, January 22, 2013 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.1 mg / 0.02 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Watson Laboratories, Inc.'s Lutera(R) 28 Tablets. Lupin's Levonorgestrel and Ethinyl Estradiol Tablets are a...

2013-01-07 00:20:30

SAN FRANCISCO, Jan. 7, 2013 /PRNewswire/ -- Big pharma companies are facing a widening "growth gap" that will increase pressure to drive growth through mergers and acquisitions (M&A). But big pharma's attempts to make deals will be challenged by its diminished resources and fiercer competition for attractive assets from rapidly growing big biotech and specialty pharma companies. These and other findings were released today by Ernst & Young in the report Closing...

2012-12-28 12:22:34

PITTSBURGH, Dec. 28, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of Pfizer's Dilantin® Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal...

2012-12-28 12:22:29

PITTSBURGH, Dec. 28, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its partner Famy Care Ltd. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg. This product is the generic version of Teva Branded Pharmaceutical Products' Nordette® 28 Tablets, which are indicated for the prevention of pregnancy in women who elect to use this...

2012-12-18 12:27:12

PITTSBURGH, Dec. 18, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quinine Sulfate Capsules USP, 324 mg. This product is the generic version of Mutual Pharmaceutical Company, Inc.'s Qualaquin(®) Capsules, and is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum...

2012-11-29 08:28:51

PITTSBURGH, Nov. 29, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tolterodine Tartrate Tablets, 1 mg and 2 mg. This product is the generic version of Pharmacia and Upjohn's Detrol(®) Tablets and is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency,...

2012-11-13 08:34:27

PITTSBURGH, Nov. 13, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sildenafil Citrate Tablets, 20 mg. This product is the generic version of Pfizer's Revatio®, which is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening....

2012-10-18 07:26:26

MUMBAI, India and BALTIMORE, Maryland, October 18, 2012 /PRNewswire/ -- BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its oral contraceptive Kurvelo(R) Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP) 0.15 mg/0.03 mg from the United States Food and Drugs Administration (FDA) to market a generic...